Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Amgen grants GDNF rights to MedGenesis, Biovail

Executive Summary

Amgen has granted drug delivery start-up MedGenesis Therapeutix and Biovail Laboratories International SRL co-exclusive rights to its glial cell line-derived neurotrophic factor (GDNF) for therapeutic uses. Specifically MedGenesis has a worldwide license to GDNF for all indications, and Biovail has rights--for CNS areas only--in the US, Canada, Japan, and some European territories. Amgen has purchased a small, undisclosed amount of MedGenesis stock.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies